Tarsons Products Valuation
Is TARSONS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of TARSONS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: TARSONS (₹379.85) is trading above our estimate of fair value (₹165.06)
Significantly Below Fair Value: TARSONS is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for TARSONS?
Key metric: As TARSONS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is TARSONS's PE Ratio? | |
|---|---|
| PE Ratio | 58.5x |
| Earnings | ₹345.49m |
| Market Cap | ₹20.95b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 6.8x |
| Enterprise Value/EBITDA | 24.7x |
| PEG Ratio | 2.1x |
Price to Earnings Ratio vs Peers
How does TARSONS's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 42.2x | ||
WINDLAS Windlas Biotech | 31.6x | n/a | ₹20.0b |
524394 Vimta Labs | 34.4x | n/a | ₹16.5b |
544184 Borosil Scientific | 56.1x | n/a | ₹16.1b |
INNOVACAP Innova Captab | 46.8x | 29.7% | ₹53.3b |
TARSONS Tarsons Products | 58.5x | 27.7% | ₹20.9b |
Price-To-Earnings vs Peers: TARSONS is expensive based on its Price-To-Earnings Ratio (58.5x) compared to the peer average (42.2x).
Price to Earnings Ratio vs Industry
How does TARSONS's PE Ratio compare vs other companies in the Asian Life Sciences Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: TARSONS is expensive based on its Price-To-Earnings Ratio (58.5x) compared to the Asian Life Sciences industry average (30.7x).
Price to Earnings Ratio vs Fair Ratio
What is TARSONS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 58.5x |
| Fair PE Ratio | 35.6x |
Price-To-Earnings vs Fair Ratio: TARSONS is expensive based on its Price-To-Earnings Ratio (58.5x) compared to the estimated Fair Price-To-Earnings Ratio (35.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | ₹379.85 | ₹597.75 +57.4% | 22.2% | ₹760.00 | ₹430.00 | n/a | 4 |
| Nov ’25 | ₹407.65 | ₹551.25 +35.2% | 26.1% | ₹700.00 | ₹407.00 | n/a | 4 |
| Oct ’25 | ₹448.50 | ₹551.25 +22.9% | 26.1% | ₹700.00 | ₹407.00 | n/a | 4 |
| Sep ’25 | ₹452.30 | ₹551.25 +21.9% | 26.1% | ₹700.00 | ₹407.00 | n/a | 4 |
| Aug ’25 | ₹507.55 | ₹570.50 +12.4% | 25.6% | ₹740.00 | ₹407.00 | n/a | 4 |
| Jul ’25 | ₹508.95 | ₹566.75 +11.4% | 25.0% | ₹725.00 | ₹407.00 | n/a | 4 |
| Jun ’25 | ₹414.15 | ₹649.00 +56.7% | 14.6% | ₹770.00 | ₹511.00 | n/a | 4 |
| May ’25 | ₹459.20 | ₹649.00 +41.3% | 14.6% | ₹770.00 | ₹511.00 | n/a | 4 |
| Apr ’25 | ₹426.70 | ₹644.00 +50.9% | 13.8% | ₹750.00 | ₹511.00 | n/a | 4 |
| Mar ’25 | ₹468.30 | ₹644.00 +37.5% | 13.8% | ₹750.00 | ₹511.00 | n/a | 4 |
| Feb ’25 | ₹492.55 | ₹647.00 +31.4% | 15.9% | ₹760.00 | ₹511.00 | n/a | 3 |
| Jan ’25 | ₹527.40 | ₹644.25 +22.2% | 13.9% | ₹760.00 | ₹511.00 | n/a | 4 |
| Dec ’24 | ₹471.70 | ₹637.40 +35.1% | 13.3% | ₹760.00 | ₹511.00 | n/a | 5 |
| Nov ’24 | ₹467.65 | ₹661.60 +41.5% | 9.9% | ₹775.00 | ₹590.00 | ₹407.65 | 5 |
| Oct ’24 | ₹526.00 | ₹671.40 +27.6% | 9.2% | ₹775.00 | ₹590.00 | ₹448.50 | 5 |
| Sep ’24 | ₹526.70 | ₹691.75 +31.3% | 7.5% | ₹775.00 | ₹636.00 | ₹452.30 | 4 |
| Aug ’24 | ₹611.65 | ₹716.75 +17.2% | 13.0% | ₹875.00 | ₹636.00 | ₹507.55 | 4 |
| Jul ’24 | ₹602.25 | ₹710.50 +18.0% | 11.7% | ₹850.00 | ₹636.00 | ₹508.95 | 4 |
| Jun ’24 | ₹570.85 | ₹740.25 +29.7% | 9.6% | ₹850.00 | ₹666.00 | ₹414.15 | 4 |
| May ’24 | ₹565.40 | ₹786.75 +39.1% | 8.6% | ₹900.00 | ₹722.00 | ₹459.20 | 4 |
| Apr ’24 | ₹532.15 | ₹786.75 +47.8% | 8.6% | ₹900.00 | ₹722.00 | ₹426.70 | 4 |
| Mar ’24 | ₹591.00 | ₹808.33 +36.8% | 8.1% | ₹900.00 | ₹755.00 | ₹468.30 | 3 |
| Feb ’24 | ₹686.25 | ₹841.67 +22.6% | 13.3% | ₹1,000.00 | ₹755.00 | ₹492.55 | 3 |
| Jan ’24 | ₹694.45 | ₹851.67 +22.6% | 14.8% | ₹1,030.00 | ₹755.00 | ₹527.40 | 3 |
| Dec ’23 | ₹701.95 | ₹851.67 +21.3% | 14.8% | ₹1,030.00 | ₹755.00 | ₹471.70 | 3 |
| Nov ’23 | ₹762.90 | ₹862.00 +13.0% | 11.9% | ₹1,000.00 | ₹756.00 | ₹467.65 | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Caplin Point Laboratories
₹148.3b
Engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India.
CAPLIPOINT
₹1,952.15
7D
-0.09%
1Y
60.0%
Bal Pharma
₹2.1b
Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.
BALPHARMA
₹130.88
7D
14.0%
1Y
21.4%
Vilin Bio Med
₹313.9m
Engages in the manufacture and sale of pharmaceutical products in India.
VILINBIO
₹22.50
7D
-4.9%
1Y
6.1%